#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Retinopathy of prematurity Systemic candida Cutaneous T-cell lymphoma stage II Tuberous sclerosis complex Neuroendocrine tumour Mucopolysaccharidosis II Dupuytren's contracture Hereditary hypophosphataemic rickets Leukaemia Systemic sclerosis pulmonary Arginase deficiency Acquired ATTR amyloidosis Heart disease congenital Philadelphia chromosome positive Biotinidase deficiency More trials…

    Learn about Rare Diseases

    Systemic mastocytosis – Treatment Mastocytosis – Treatment Sjogren’s syndrome – Treatment Basal cell naevus syndrome – Trials in Disease Fabry’s disease – Life with Disease Prader-Willi syndrome – Treatment Waldenstrom’s macroglobulinaemia refractory – Treatment Splenic marginal zone lymphoma – Diagnostics Noonan syndrome – Basic Information Primary biliary cholangitis – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Df1001 Rbl016.2 A49 Pramipexole Avapritinib Soft Paraffin And Fat Products TALADEGIB L-Histidine Apg777 Asfotase Alfa Bi 3032950 Quizartinib Dihydrochloride Erdafitinib AP31969 SULFATE Alpelisib Atidarsagene Autotemcel Idursulfase Mebeverine Hydrochloride Artemisia Vulgaris (312) Rbl027.2 More therapies…

    Learn about Your Condition

    Type 2 diabetes mellitus Sarcoidosis Spina bifida Endometriosis Vomiting Hypoparathyroidism Malignant peritoneal neoplasm Ovarian cancer metastatic Chorioretinitis Oropharyngeal cancer recurrent Orthostatic hypotension Perthes disease Neuromuscular scoliosis Glucose tolerance impaired Pyelonephritis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Neoplasm

  • Phase 1/2 Study of ter-2013-01, imlunestrant, and fulvestrant in patients with solid tumors with AKT/PI3K/PTEN pathway alterations

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Fulvestrant
    • Ly3484356
    Belgium

  • Study of BMS-986504 alone or in drug combination in adults with advanced or metastatic solid tumors with MTAP deletion

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Temozolomide
    • 2-[4-[4-(AMINOMETHYL)-1-OXO-2H-PHTHALAZIN-6-YL]-2-METHYLPYRAZOL-3-YL]-4-CHLORO-6-CYCLOPROPYLOXY-3-FLUOROBENZONITRILE
    • Carboplatin
    Belgium France Germany Ireland Italy Norway +1

  • Study of IDE849, IDE‑161 and durvalumab evaluating safety and efficacy in patients with DLL3‑positive tumors including small cell lung cancer

    Not yet recruiting

    1 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Durvalumab
    France Spain

  • Safety and Tolerability of Inhaled KB707 with or without Docetaxel in Patients with Advanced Lung Solid Tumors

    Not yet recruiting

    1 1 1 1
    Investigated Drugs:
    • Docetaxel
    France Spain

  • REGN10597 Alone or with Cemiplimab in Adults with Advanced Solid Tumours, Melanoma, or Clear-Cell Renal-Cell Carcinoma

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    • Clear cell renal cell carcinoma
    • Neoplasm
    Investigated Drugs:
    • Cemiplimab
    France Germany Italy Spain

  • Safety and Preliminary Efficacy of Oral GSK5460025A Alone or with Drug Combination in Adult Patients with dMMR/MSI‑H Colorectal Cancer

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • GSK5460025A
    Denmark France Italy The Netherlands Spain Sweden
Previous Page
1 … 10 11 12 13 14 … 25
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!